Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues

详细信息    查看全文

• 作者：Ali Salavati ; MD ; MPH^* ; ^&dagger ; ; Ameya Puranik ; MBBS ; DNB ; MNAMS^&Dagger ; ; Harshad R. Kulkarni ; MD^§ ; ; Hendra Budiawan ; MD^║ ; Richard P. Baum ; MD ; PhD^§ ; ; ^{richard.baum@zentralklinik.de" class="auth_mail" title="E-mail the corresponding author}
• 刊名：Seminars in Nuclear Medicine
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：46
• 期：3
• 页码：215-224
• 全文大小：1782 K

文摘

As therapeutic options in advanced medullary and non–iodine avid differentiated (nonmedullary) thyroid cancers are limited and associated with significant toxicity, targeting of somatostatin receptors (SSTRs) for internal radiation therapy provides a promising option. Theranostics (therapy and diagnosis) using radiolabeled somatostatin analogues has proved to be a milestone in the management of SSTR-expressing tumors. Peptide receptor radionuclide therapy using ¹⁷⁷Lu-labeled or ⁹⁰Y-labeled somatostatin analogues may have a significant role in the management of medullary and nonmedullary thyroid cancers in those patients where PET/CT with ⁶⁸Ga-labeled somatostatin analogues demonstrates significant SSTR expression.